Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study.

Toshiharu Hirose,Shun Yamamoto,Kotoe Oshima,Hidekazu Hirano,Natsuko Okita Tsuda,Hirokazu Shoji,Satoru Iwasa,Yoshitaka Honma,Atsuo Takashima,Narikazu Boku,Zyunya Oguma,Koshiro Ishiyama,Hiroyuki Daiko,Ken Kato

Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable esophagogastric junction adenocarcinoma: A retrospective study.

2021

Toshiharu Hirose
Shun Yamamoto
Kotoe Oshima
Hidekazu Hirano
Natsuko Okita Tsuda
Hirokazu Shoji
Satoru Iwasa
Yoshitaka Honma
Atsuo Takashima
Narikazu Boku
Zyunya Oguma
Koshiro Ishiyama
Hiroyuki Daiko
Ken Kato

209Background: In Western countries, 5-FU plus leucovorin, oxaliplatin, docetaxel (DTX) (FLOT) is the standard perioperative treatment for resectable gastric adenocarcinoma and esophagogastric junc...

Keywords:

Docetaxel
Retrospective cohort study
Fluorouracil
Medicine
Internal medicine
Oxaliplatin
Perioperative
Cisplatin
esophagogastric junction
Gastroenterology
Adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations